KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Cash from Financing Activities (2016 - 2026)

Thermo Fisher Scientific filings provide 18 years of Cash from Financing Activities readings, the most recent being $1.1 billion for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities rose 1171.57% to $1.1 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $3.0 billion, a 159.06% increase, with the full-year FY2025 number at $1.8 billion, up 126.52% from a year prior.
  • Cash from Financing Activities hit $1.1 billion in Q1 2026 for Thermo Fisher Scientific, down from $3.5 billion in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $3.5 billion in Q4 2025 to a low of -$3.7 billion in Q4 2024.
  • Median Cash from Financing Activities over the past 5 years was -$991.0 million (2025), compared with a mean of -$607.6 million.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 2406.58% in 2022 and later soared 1328.48% in 2023.
  • Thermo Fisher Scientific's Cash from Financing Activities stood at $2.4 billion in 2022, then tumbled by 159.72% to -$1.4 billion in 2023, then plummeted by 156.72% to -$3.7 billion in 2024, then surged by 196.18% to $3.5 billion in 2025, then plummeted by 69.0% to $1.1 billion in 2026.
  • The last three reported values for Cash from Financing Activities were $1.1 billion (Q1 2026), $3.5 billion (Q4 2025), and -$632.0 million (Q3 2025) per Business Quant data.